Ultrashort Nasdaq Biotech Proshares (BIS) 31.97

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2015 at 9:50 PM

Ultrashort Nasdaq Biotech Proshares (BIS) 31.97 $BIS

What The ECB Will Do
Chuck Butler - Daily Reckoning - Tue Jun 30, 9:35AM CDT
This post What The ECB Will Do appeared first on Daily Reckoning . Chuck Butler explains the breakdown of the Greek referendum vote that will take place this Sunday, plus the euro rallies then sells off, and another week data print from New...
BIS: 31.97 (-3.60)

Two more triple-levered biotech ETFs launch
Seeking Alpha - at Seeking Alpha - Tue Jun 23, 8:22AM CDT

BBP: 31.93 (+1.42), PBE: 53.24 (+2.41), BBC: 30.36 (+0.86), SBIO: 32.44 (+1.41), BIS: 31.97 (-3.60), HQL: 25.95 (+0.80), FBT: 111.61 (+4.83), BIB: 76.19 (+6.18), XBI: 218.99 (+10.78), BBH: 126.68 (+6.09), IBB: 341.75 (+16.49), LABU: 28.76 (+3.86), LABD: 42.04 (-7.95)

Biotech Bio-Hazard
James Stefurak, CFA - at Seeking Alpha - Tue Jun 16, 10:58AM CDT

BIIB: 298.25 (+16.51), BIS: 31.97 (-3.60), GILD: 106.96 (+4.40), IBB: 341.75 (+16.49), AMGN: 153.98 (+8.79), AAPL: 109.69 (+5.95), CELG: 119.23 (+6.53)

Why I'm Shorting Biotech
George Budwell, The Motley Fool - Motley Fool - Sat Jun 13, 12:16PM CDT
Biotech and biopharma have had an incredible run over the past few years. And like many investors, I've been able to crush the broader markets simply by buying and holding top names in the industry like AbbVie , Gilead Sciences , and Isis...
ESRX: 84.10 (+3.18), BIS: 31.97 (-3.60), ISIS: 49.02 (+2.57), GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), IBB: 341.75 (+16.49), ABBV: 63.14 (+2.43), BMY: 60.03 (+2.15), CELG: 119.23 (+6.53)

Intro Guide to Leveraged Biotech ETF Investing - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Tue Jun 09, 11:08AM CDT
A quick discussion of the ways investors can play the biotechnology sector with leverage.
BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), LABU: 28.76 (+3.86), LABD: 42.04 (-7.95)

When Genius Fails Again, Part I
Addison Wiggin - Daily Reckoning - Fri May 22, 3:06PM CDT
This post When Genius Fails Again, Part I appeared first on Daily Reckoning . Addison takes a look behind the curtain during a seminal moment in The Daily Reckoning’s history… The post When Genius Fails Again, Part I appeared first on Daily...
BIS: 31.97 (-3.60)

Hidden Gems In This Market Cycle's Leading Theme
Cam Hui, CFA - Seeking Alpha - Fri May 08, 5:18AM CDT
Philosophical Economics wrote a terrific post yesterday about how the "Winner take all" economy is affecting companies and the competitive environment. He observed that net margins have been elevated in the last few years. Generally, when...
BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49)

FDA to hold public meeting on off-label drug promotion
Seeking Alpha - at Seeking Alpha - Thu May 07, 10:13AM CDT

ABT: 43.98 (+1.08), BIB: 76.19 (+6.18), PFE: 32.43 (+1.09), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69), LLY: 81.10 (+2.84), BMY: 60.03 (+2.15), GSK: 40.47 (+1.06), JNJ: 95.11 (+4.38), BIS: 31.97 (-3.60), AZN: 31.13 (+0.85), MRK: 54.42 (+3.25), ABBV: 63.14 (+2.43), SNY: 49.13 (+1.30), IRY: 50.97 (+0.55), IXJ: 104.48 (+3.69), NVS: 97.13 (+1.99)

Biotechs continue slide
Seeking Alpha - at Seeking Alpha - Wed Apr 29, 11:42AM CDT

BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49)

Drug makers getting visability over aggressive pricing practices
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 10:19AM CDT

MNK: 85.82 (+7.16), BIS: 31.97 (-3.60), VRX: 227.24 (+7.16), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69)

U.S. drug spending rose 13% in 2014
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 6:28AM CDT

BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69), IXJ: 104.48 (+3.69), IRY: 50.97 (+0.55)

Infographic: Developing Economies Graying Faster
The Financialist - at Seeking Alpha - Thu Apr 09, 4:38PM CDT
(click to enlarge) Original post Read comments Read more articles from Seeking Alpha: Our Second Best Performing Stock For First Quarter 2015 - Maiden Holdings, Ltd. Rich Middle Class, Poor Middle Class Why Investors Shouldn't...
BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69), IXJ: 104.48 (+3.69), IRY: 50.97 (+0.55)

BUYINS.NET: BIS, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Tue Mar 31, 4:21AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
BIS: 31.97 (-3.60)

BIS vs. IBB is The 'Chart of the Day'
at The Street - Thu Mar 26, 9:14AM CDT
The BIS vs. IBB is the OptionsProfits 'Chart of the Day.'
BIS: 31.97 (-3.60), IBB: 341.75 (+16.49)

Biotechs selling off on increased volume
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:13AM CDT

BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49)

FDA to assess homeopathy business
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:42PM CDT

BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69), IXJ: 104.48 (+3.69), IRY: 50.97 (+0.55)

2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 51.34 (+1.24), GFI: 2.72 (-0.10), BIS: 31.97 (-3.60), ACH: 7.57 (-0.24), BOI: 14.84 (+0.10)

Pharma and Biotech M&A deals reached $212B last year
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 10:45AM CDT

BIS: 31.97 (-3.60), BIB: 76.19 (+6.18), IBB: 341.75 (+16.49), DRGS: 60.10 (-0.69), IXJ: 104.48 (+3.69), IRY: 50.97 (+0.55)

BlackIce Enterprise Sponsors Vietnam Seminar on Basel II Implementation
ACCESSWIRE - Tue Jan 13, 4:02PM CST
Vancouver, BC / ACCESSWIRE / January 13, 2015 / BlackIce Enterprise Risk Management Inc. (BlackIce) (CSE: BIS), along with IBM, is a co-sponsor of the 'Leverage ICAAP for Basel II Implementation' seminar to be held in Hanoi, Vietnam on Thursday January 15, 2015.
BIS: 31.97 (-3.60), IBM: 146.70 (+5.74)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...